Top executives from a slate of the world’s biggest pharma companies will be rubbing shoulders with Bill Gates today as they roll out an ambitious plan to join hands on a $785 million effort to develop new drugs and distribute therapies designed to erad…
Archive for the ‘Abbott Labs’ Category
13 Big Pharmas to collaborate on $785M fight against neglected diseases
January 30th, 2012 
John Carroll 
Posted in Abbott Labs, Andrew Witty, Big Pharma, Bill and Melinda Gates Foundation, Blog, Companies, Diagnostics, Funding, GlaxoSmithKline, Medical Devices, Medical Supply, Pfizer, Pharmaceuticals, Startups, Universities, Videos, World Health Organization 
Tags: biotech food social media 
Comments OffJPM kicks off with fevered focus on the next big biotech deal
January 9th, 2012 John Carroll The news of the Bristol-Myers/Inhibitex deal couldn’t have been better timed. With the biotech world converging on San Francisco today for the annual JP Morgan confab, there’s nothing like a 10-figure deal to get everyone whipped up about the potential…
Posted in Abbott Labs, Achillion, Biotech IPO, Blog, Boehringer Ingelheim, Bristol-Myers Squibb, Companies, Diagnostics, Funding, Hepatitis C, Idenix Pharmaceuticals, Inhibitex, Medical Devices, Medical Supply, Merck, Mergers and Acquisitions, Novartis, Pharmaceuticals, Pharmasset, Roche, Startups, Universities, vertex, Videos Tags: biotech food social media Comments OffAbbott nixes cancer drug alliance with Emergent BioSolutions
December 29th, 2011 Ryan McBride Emergent BioSolutions ($EBS) has suffered a setback in its campaign to expand into cancer drug development. Abbott Labs ($ABT) has decided to dump a partnership with Emergent on the development of the protein therapeutic TRU-016 against B-cell mal…
Posted in Abbott Labs, Big Pharma, Blog, Cancer Drugs, Companies, Diagnostics, Emergent BioSolutions, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos Tags: biotech food social media Comments OffUPDATED: Abbott bets $400M on mega-blockbuster future for Reata program
December 12th, 2011 John Carroll Abbott ($ABT) has essentially doubled down on its high-stakes gamble that Reata Pharmaceuticals has the inside track on improving renal function in patients with chronic kidney disease, agreeing to plunk down $400 million in cash to gain an equal stake…
Posted in Abbott Labs, bardoxolone, Blog, Companies, Diagnostics, Funding, kidney disease, Medical Devices, Medical Supply, Pharmaceuticals, Reata Pharmaceuticals, Startups, Universities, Videos Tags: biotech food social media Comments Off